Obesity is associated with insulin resistance, hypertension, and cardiovascular disease, but the mechanisms underlying these associations are incompletely understood. Microvascular dysfunction may play an important role in the pathogenesis of both insulin resistance and hypertension in obesity.
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The high prevalence of obesity throughout the world has increasingly focused on the association between body weight, cardiovascular risk factors and clinical cardiovascular disease.(1) Body fat distribution may be more strongly associated with obesity-related comorbidities and cardiovascular disease compared with generalized measures of adiposity, such as body mass index (BMI). (2) (3) (4) (5) In humans and most animal models, the development of obesity leads not only to increased fat depots in classical adipose tissue locations but also to significant lipid deposits within and around other tissues and organs, a phenomenon known as ectopic fat storage. Ectopic fat, defined as the deposition of fat in non-classical locations including the heart, kidneys and blood vessels, may contribute to the development of cardiovascular disease by exerting a local toxic effect on adjacent structures. (6) (7) (8) One such ectopic fat depot is perivascular adipose tissue (PVAT), which is directly adherent to blood vessels. PVAT includes fat surrounding large arteries, as well as organ-specific fat depots in which adipose tissue surrounds the organ's vasculature. Periaortic fat falls into the former category, whereas epicardial, pericardial and perirenal fat fall into the latter category. (9) PVAT has been shown to produce a variety of adipokines that contribute to regulation of vascular tone and local inflammation. Signaling from PVAT to the vasculature ("vasocrine" signaling) may not only cause vascular disease associated with obesity, but also reduce insulin-induced glucose disposal by reducing muscle perfusion. In recent years, evidence has emerged suggesting that this PVAT may hold one of the keys to effective future treatment or prevention of both insulin resistance and cardiovascular disease in obesity. (10) the risk of development of metabolic and cardiovascular disease. This risk appears to stem from multiple abnormalities in adipose tissue function leading to a chronic inflammatory state and to dysregulation of the endocrine and paracrine actions of adipocyte-derived factors. These, in turn, disrupt vascular homeostasis by causing an imbalance between the nitric oxide (NO) pathway and the endothelin-1 system, with impaired insulin-stimulated endothelium-dependent vasodilation. (11) It is now well established that adipose tissue is not only involved in energy storage but also functions as an endocrine organ that secretes various bioactive substances. (12, 13) The dysregulated expression of these factors, caused by excess adiposity and adipocyte dysfunction, has been linked to the pathogenesis of various disease processes through altered immune responses. (14) The expression of adipokines can also vary depending on the site of an adipose tissue depot ( Figure 1 ). The two most abundant depots are visceral and subcutaneous adipose tissues, which produce unique profiles of adipokines. (15, 16) In addition, adipocyte depots occur throughout the body in association with multiple organs, including the heart and kidneys. Adipocytes are also found in the bone marrow, lungs and the adventitia of major blood vessels. In some instances, it has been shown that high-calorie diets can promote the development of a pro-inflammatory state in these depots in a similar manner to that observed in subcutaneous and visceral adipose tissue. (17) Although the functional importance of many of these individual adipose depots is generally not known, recent evidence suggests that diet-induced changes in their adipokine secretion can influence the function of the associated tissue. (18) Accumulating evidence indicates that a state of chronic inflammation has a crucial role in the pathogenesis of obesity-related metabolic dysfunction. (19, 20) Indeed, clinical and epidemiological studies have described a clear connection between the development of low-grade inflammatory responses and metabolic diseases, particularly in the context of obesity and type 2 diabetes. Excess adipose mass (as occurs in obese individuals) is associated with increased levels of the pro-inflammatory marker C-reactive adipokin merubah pengaruh jaringan lemak perivaskular terhadap pembuluh darah. Perubahan sekresi adipokin perivaskular pada obesitas berperan terhadap perkembangan obesitas menjadi penyakit vaskular.
Introduction protein (CRP) in the blood.(21) Increased levels of CRP, and its inducer interleukin-6 (IL-6), are predictive of the development of type 2 diabetes in various populations. (21, 22) The adipose tissue provides vital information about its own mass and the whole body's nutritional status to the brain and to insulin-sensitive organs and tissues through the synthesis and secretion of a number of adipokines such as leptin, adiponectin and resistin. (23, 24) Leptin participates in the physiological regulation of appetite, by signalling the level of satiety to the brain. (25) Paradoxically, the majority of obese individuals have elevated circulating leptin levels, likely secondary to leptin resistance.(26) Furthermore, high leptin concentrations correlate with adverse cardiovascular outcomes in obese patients. (27) Adiponectin is an adipocyte-derived peptide that circulates in high concentrations in plasma (28) and whose actions include enhancement of insulin-mediated glucose uptake in skeletal muscle, suppression of hepatic glucose production and amelioration of insulin resistance. (29) Adiponectin's concentrations, unlike most of the other adipokines, are inversely correlated with BMI(30) and visceral fat (31) , and are reduced in patients with obesity and type 2 diabetes(32).
Adiponectin is one of the few adipokines that possesses multiple salutary effects on insulin sensitivity and cardiovascular health. Clinical investigations have identified adiponectin deficiency (hypoadiponectinaemia) as an independent risk factor for cardiovascular disease (CVD). In animals, elevation of plasma adiponectin by either pharmacological or genetic approaches alleviates obesityinduced endothelial dysfunction and hypertension, and also prevents atherosclerosis, myocardial infarction and diabetic cardiomyopathy. Adiponectin protects cardiovascular health through its vasodilator, anti-apoptotic, anti-inflammatory and anti-oxidative activities in both cardiac and vascular cells. (33) Resistin, an adipocyte-specific peptide in rodents, in humans is mainly produced by macrophages. It has been suggested that resistin may play a role in the development of insulin resistance and obesity (34) and that its levels may be increased in patients with type 1 and 2 diabetes (35) . Evidence suggests that resistin is involved in pathological processes leading to CVD including inflammation, endothelial dysfunction, thrombosis, angiogenesis and smooth muscle cell dysfunction. (36) Resistin possibly binds to the membrane bound toll-like receptor 4, which then activates the intracellular signalling pathway. Resistin can activate the translocation of nuclear factor (NF)kB into the nucleus, which in turn, activates the transcription of pro-inflammatory cytokine genes, contributing to the proliferation of vascular smooth muscle cells (VSMCs) and endothelial dysfunction. Activation of NFkB can also be mediated by the resistininduced activation of phosphatidylinositol 3-kinase / Akt pathway. Resistin can also stimulate the production of pro-inflammatory cytokines through mitogen-activated protein kinase (MAPK) p38 and c-Jun N-terminal kinase. Resistin can cause oxidative stress, which is another factor for MAPK activation and endothelial NO synthase (eNOS) inhibition. Resistin increases the production of superoxide anions (O 2 -), which inhibit eNOS gene expression and reduce bioavailability of NO. VSMCs proliferation and endothelial dysfunction including impaired vasorelaxation, enhanced thrombosis, hyperpermeability, angiogenesis and increased cell adhesion collectively contribute to the formation of atherosclerosis. (36) A group of adipokines, including adipocyte fatty acid binding protein (A-FABP) and lipocalin-2, possess specific lipid-binding activity and are up-regulated in obese human subjects and animal models. They act as lipid chaperones to promote lipotoxicity in endothelial cells and cause endothelial dysfunction under obese conditions. However, different small lipid-binding proteins modulate the development of vascular complications in distinctive manners, which are partly attributed to their specialized structural features and functionalities. (37) Several recent studies indicate that adipokines, such as leptin, resistin, IL-6 and tumor necrosis factor (TNF)a exert adverse effects on vasodilator function in animals with experimental obesity. These effects in part are mediated by elevated reactive oxygen species (ROS) production in the vascular wall. In obesity, during expansion of adipose tissue phenotypic changes of adipocytes occurs, which results in increased production of leptin, resistin, TNFa and IL-6. In addition to their systemic actions, these adipokines may locally induce production of O 2 -in the adipose tissue arteriole. O 2 -interferes with the availability of NO and reduces dilator function of microvessels. Altered microvascular responsiveness may provoke hypoxia in the expanded adipose tissue, which via hypoxia inducible factor (HIF)1a would exaggerate pathological changes in adipokine production. Adipocytes may also enhance monocyte chemotactic protein 1 (MCP1) synthesis, which facilitates macrophage accumulation and activation, to maintain oxidative stress and adipose tissue inflammation. (38) Obesity results in an imbalance between endotheliumderived vasoactive factors favouring vasoconstriction, cell growth and inflammatory activation. Abnormal regulation of these factors due to endothelial cell dysfunction is both a consequence and a cause of vascular disease processes. Because of the similarities of the vascular pathomechanisms activated, obesity can be considered to cause accelerated, 'premature' vascular aging. (39) and organ function in two possible ways. First, the size of fat pads around key organs may increase substantially. This could modify organ function either by simple physical compression or because peri-organ fat cells may secrete various locally acting substances. Second, lipid accumulation can occur in non-adipose cells and may lead to cell dysfunction or cell death, a phenomenon known as lipotoxicity. (6, 40, 41) Throughout the body, most arteries and veins with a diameter greater than 100 μm are in contact with/surrounded by adipocytes. The term "perivascular adipose tissue" refers to adipose tissue around vessels, irrespective of location. Known locations of PVAT include the coronaries (epicardial adipose tissue) (42) , aorta (periaortic adipose tissue) (43) , and the microvascular beds of the mesentery(44), muscle (45) , kidney (6) , and adipose tissue (46) .
PVAT consists of adipocytes, fibroblasts, stem cells (47) , mast cells (48, 49) , and nerves (48) . PVAT is initially formed in the embryological phase and remains in place throughout life; in times of nutrient abundance and obesity, PVAT expands and undergoes an inflammatory transformation. The volume of PVAT is associated with the quantity of intra-abdominal adipose tissue (50, 51) . Accumulating evidence suggests that the products of PVAT (ie, adipokines) contribute to regulation of vascular function. In this regard, both protective physiologic and pathologic properties of PVAT have been proposed (10) .
Ectopic fat storage in the heart
Most animal models of obesity as well as obese humans show an increased cardiac mass. In the rabbit model of obesity, a 50% gain in body weight led to an increase in dry weight of the right and left ventricles by about 70 and 50%, respectively, and to an increase in protein content by about 50% in both right and left ventricles.(52) Overall, those changes led to significant alterations in cardiac function. To what extent the cardiac changes observed in obesity are due to ectopic fat storage is not clear. In fact, the combination of a mild increase in blood pressure, increase in cardiac output, increase in the heart rate-pressure product, and ectopic fat storage within and around the heart, could have additive effects resulting in the frequent observation of systolic and diastolic dysfunctions in obesity, which in the long term promote heart failure. (6) Ectopic fat storage around blood vessels Nearly, all blood vessels in the body are surrounded by variable amounts of adventitial fat. Traditionally, perivascular fat has been assumed to serve as structural support for the vasculature. However, perivascular fat
In humans and most animal models, the development of obesity leads not only to increased fat depots in classical adipose tissue locations but also to significant lipid deposits within and around other tissues and organs (ectopic fat storage). With fat gain, lipid deposition can impair tissue Ectopic Fat Storage in Heart and Blood Veseel has been shown to modulate vascular responsiveness to vasoactive agents in studies of the aorta (53, 54) and of the mesenteric vessels (44) . Interestingly, diet-induced fat deposition in experimental models of obesity is not limited to the subcutaneous fat and to the classical visceral depots in tight connection with mediastinic and abdominal organs, but also occurs along the major blood vessels. (55) The pathophysiological consequences of increased perivascular fat in obesity could simply be mechanical. As more adipose tissue wraps around blood vessels, it is conceivable that the large amounts of perivascular fat could contribute to the increased vascular stiffness often observed in obese subjects. Excess body weight is associated with higher aortic stiffness as determined by magnetic resonance imaging techniques (56) or by aortic pulse wave velocity measurements. (57) What is worrisome is that the strength of this association can be seen in very young adults. (57) In fact, noninvasive measurements of the carotid artery by ultrasound imaging in severely obese children revealed a significantly greater carotid stiffness. (58) In addition, perivascular fat could act as a secretory organ to influence the neighboring blood vessels. This function of perivascular fat is very intriguing since studies in isolated blood vessels have shown that the contractile response of rat aortic rings to angiotensin II, serotonin and phenylephrine was significantly attenuated in the presence of periadventitial fat. (54) Ectopic fat storage in the kidney The development of obesity-induced hypertension in dogs(59) and rabbits(60) is associated with significant sodium retention in spite of a marked increase in GFR. Analysis of renal artery pressure-sodium excretion relationship in obese dogs fed an HFD for 5-6 weeks reveals a shift to the right as well as a decrease of the slope of the pressure-natriuresis curve.(61) Many mechanisms (62) have been suggested to explain this abnormal sodium handling, including increased renal nerve sympathetic activity, activation of the renin-angiotensin-aldosterone system, as well as direct sodium-retaining effects of insulin. In addition, there is evidence that weight gain is associated with abnormal physical forces within the kidney that could promote sodium retention. (63) The mechanisms by which weight-gain leads to abnormal intrarenal physical forces are complex, but could be related to the marked structural renal changes observed in animal models of diet-induced obesity (dogs, rabbits). Accumulation of fat in the renal sinus (sinus lipomatosis) may favor compression of the renal inner medulla and of hilum structures.(6) Taken together, ectopic fat storage in key target-organs of cardiovascular control may impair their functions, contributing to the increased prevalence of cardiovascular diseases in obese subjects.
Fifty years ago, the vision of vascular control was rather simple: besides local metabolites directly governing the opening of arterioles in function of the needs of the tissues, daily vascular regulation was pretty much the affair of the omnipotent sympathetic adrenergic nervous system. A first glimpse of the importance of local modulation of the control of vascular tone came with the realization that a number of factors could impinge on the adrenergic nerve endings and reduce or augment the amount of noradrenaline released per nerve impulse reaching the adrenergic varicosities. (64) A further fundamental breakthrough was the discovery that endothelial cells could initiate relaxations (65) or contractions(66) of the underlying vascular smooth muscle, permitting the concept of endothelium-dependent control of vascular tone. (67, 68) Thirty years later we know a lot about nitric oxide, endothelium-dependent hyperpolarization, endothelins and endothelium-derived vasoconstrictor prostaglandins but we still do not understand all the complexities of endothelial control. (69) (70) (71) (72) (73) (74) (75) Both in the animal and in humans, obesity results in progressive endothelial dysfunction, not only in large arteries, but also at the level of the microcirculation, which then helps us to understand why it is a major risk factor for cardiovascular disease. (11, 28, 38, 39) Obesity has detrimental effects on the microcirculation. Functional changes in microvascular responsiveness may increase the risk of developing cardiovascular complications in obese patients. Emerging evidence indicates that selective therapeutic targeting of the microvessels may prevent lifethreatening obesity-related vascular complications, such as ischaemic heart disease, heart failure and hypertension. It is also plausible that alterations in adipose tissue microcirculation contribute to the development of obesity. (38) Although most of the systemic arteries except the cerebral vasculature are surrounded by PVAT, the functional role of PVAT other than as a structural support of the blood vessel has long been neglected. Recent studies, however, indicate a crucial role of PVAT not only in the regulation of blood vessel function but also in its structure.(76) PVAT secretes more pro-inflammatory cytokines such as IL-6, IL-8 and MCP-1 than subcutaneous adipose tissue. (17) Because PVAT encroaches into the adventitia without an anatomical barrier, it is suggested that humoral factors secreted by PVAT easily access the blood vessel wall, indicating that PVAT functions as a paracrine organ that transduces metabolic signals to blood vessels.
Today's paradigm holds that the vascular wall consists PVAT as Regulator of Vascular Function vessel contraction. Lohn et al. described in 2002 the so-called "adventitium-derived relaxing factor" (ADRF), which was shown to be produced by isolated adipocytes and diminished the contractile response of intact aortic rings to serotonin, angiotensin II, or phenylephrine.(54) They suggested that PVAT release a transferable ADRF that acts by tyrosine kinase-dependent activation of potassium channels in vascular smooth muscle cells. The molecular nature of ADRF is still unknown; however, its presence has been confirmed in small mesenteric arteries.(88) ADRF acts independently of leptin receptors; however, leptin itself was also able to diminish angiotensin II-induced vasoconstriction by leptin receptor-mediated inhibition of intracellular calcium increase in smooth muscle cells of the rat aorta. (89) Result from study by Fesus et al. , demonstrated that the anti-contractile effects of perivascular fat occur through access of ADRF from outside the vessel ('outside control'). (86) The possible contribution by perivascular adipocytes to the regulation of vascular tone and to vascular remodeling appears to be especially important because of the current obesity epidemic that has resulted in increased numbers of diabetic and hypertensive patients. If perivascular adipocytes react like adipocytes in other depots, a dysregulation of the secretion of vasoactive and proinflammatory molecules can then be expected. (90) Recent studies explored the possibility that ADRF might be a volatile, gaseous mediator that disappears into the atmosphere during purification. (91) Previously, studies demonstrated that NO is not ADRF. (44, 54) The possibility that ADRF might be another biological active gaseous mediator, such as H 2 S or carbon monoxide (CO). H 2 S is a newly discovered physiologic vasorelaxant generated by cystathionine gamma lyase (CSE). (92) This enzyme is expressed in PVAT and endogenously generates H 2 S. (93) Fang et al. obtained similar results with CSE inhibitors in the rat aorta. In an elegant series of experiments, they measured endogenous H 2 S production in the aorta and found that serotonin, phenylephrine and angiotensin II increase H 2 S release from PVAT. Release of H 2 S is decreased with aging of rats and can be blocked by CSE inhibitors. (94) Nonetheless, the data indicate that H2S represents a candidate or modulator of ADRF.
ADRF is released by visceral periadventitial adipocytes and primarily produces endotheliumindependent vasorelaxation by opening Kv channels of 3 layers: the tunicae intima, media, and adventitia. Chalkadov et al. suggest that PVAT may indeed be considered the fourth, outermost vascular layer, that is, tunica adiposa. Because there is a lack of any fascia-like structure between the adventitia and the PVAT. (77, 78) PVAT is a producer of a large number of bioactive molecules such as adipokines (77) (78) (79) (80) , which, in a paracrine way, may exert proinflammatory and smooth muscle cell growth/migration promoting, in fact, atherogenic effects(79) and PVAT releases vasorelaxing factor(s) (81) , which may benefit the vascular biology, hence, a question whether PVAT is an enemy or a friend of the artery may emerge (82) .
Recent in vitro and in vivo evidence identifies adipose tissue as a critical endocrine organ that secretes a variety of bioactive signalling molecules into the circulation. These molecules include vascular endothelial growth factor (VEGF), IL-6, IL-1, TNFa, leptin, adiponectin (ACRP30), resistin, omentin, acylation stimulation protein (ASP), apelin, adipsin, agouti, insulin-like growth factor (IGF-1), angiotensinogen, plasminogen activator protein (PAI-1), ROS and sex steroids. (83) (84) (85) These substances can play an autocrine role in the regulation of adipocyte metabolism. Upon secretion into the bloodstream, they can also play an endocrine role in the regulation of other cellular processes, including vascular function and peripheral resistance.
Although adiponectin has been reported to relax aortic and mesenteric artery by opening voltage-dependent K + (Kv) channels (46, 86) , adiponectin is not an adipocytederived relaxing factor because the anti-contractile effects of PVAT are preserved in adiponectin-deficient mice (86) . Intriguingly, PVAT enhances the arterial contractile response to perivascular nerve stimulation through NADPH oxidasemediated superoxide production.(87) Therefore, PVAT from normal animals has a dual role in the regulation of blood of the anti-contractile effect of healthy PVAT. This makes sense because accumulation of lipid and infiltration of inflammatory cells into the PVAT may cause hypoxia, and hypoxia is known to induce oxidative stress and cytokine production. (96) The PVAT of obese patients may cause structural remodeling of the blood vessel. The thickness including adventitia and PVAT in the carotid artery is increased in patients with diabetes and dyslipidemia, and the thickness is correlated with intima-media thickness of the carotid artery. (97) in the plasma membrane of smooth muscle cells. (95) Kv7 family of potassium (KCNQ) channels exhibit a large hyperpolarisation reserve and are enabled to fulfil physiological vasodilatory functions in the presence of perivascular fat, i.e. in response to ADRF. Moreover, since ADRF is released from perivascular adipocytes, KCNQ channels seem to play a unique role for vasodilatory signals from outside the vessel ('outside control'). KCNQ channels are not targeted by endothelium-derived relaxing factors (EDRF) ('inside control'), including NO, prostaglandin I2 (prostacyclin) and endothelium-derived hyperpolarizing factor (EDHF).(95) KCNQ channels are also not targeted by other perivascular candidates, such as H 2 O 2 , superoxide and Angiotensin 1-7. The data support the novel concept that ADRF H 2 S is the physiological activator of KCNQ channels, at least in part, in visceral arteries.
The dilator effect of PVAT in patients with obesity and metabolic syndrome is lost. (46) The obese phenotype of PVAT could be mimicked by addition of inflammatory cytokines such as TNFα or IL-6 to healthy PVAT, confirming a pivotal role of adipokines in blood vessel dysfunction. This study also showed that hypoxia resulted in the loss 
PVAT and Cardiometabolic Diseases
Atherosclerosis is traditionally viewed as a disease of the vascular intima, following a paradigm of endothelial cell dysfunction, inflammatory cell recruitment, and foam cell formation. PVAT is significantly correlated with most cardiometabolic risk factors and coronary artery calcification (CAC) in the JHS cohort. The results suggest that PVAT is an important VAT depot that may exert a local effect on the coronary vasculature. (115) Preservation of PVAT may be as important as preservation of endothelium for a successful vascular intervention.
Yudkin et al. originally postulated that PVAT might hold the key to linking obesity with the development of metabolic syndrome and diabetes as a result of an adverse influence upon the vasculature. (45) In health, PVAT could produce adipokines that profoundly influence metabolism and the control of local vascular tone via vasocrine actions. It was suggested that the loss of such substances would result in a change in vascular function and development of insulin resistance. (98) As mentioned above, vascular function and especially microvascular blood volume in muscle are related to insulin sensitivity. Because obesity is associated with insulin resistance, reduction of microvascular blood volume, and altered properties of PVAT, we have proposed that PVAT causes microvascular dysfunction and insulin resistance in obesity. (45) Although there are, at present, no studies that prospectively link PVAT to diabetes, a number of studies provide indirect evidence for this hypothesis. (10) First, several studies suggest that ectopic adipose tissue, especially within muscles, strongly relates to insulin sensitivity. The amount of PVAT surrounding the brachial artery (51) and adipose tissue between muscle (intermuscular adipose tissue (IMAT))(116) are inversely related to insulin sensitivity. Even though IMAT accounts for only 3% of total periadventitial adipose depot is a functional component of the vasculature, exerting paracrine influences on blood vessel contractility. (44, 54) By virtue of their unique functional and biochemical properties, perivascular adipocytes may play a primary role in establishing adventitial inflammation in atherosclerosis. (17) Obesity is associated with inflammation of adipose tissue (24, 105) Much of the evidence demonstrating the association of obesity with adipose inflammation comes from the study of visceral adipose tissue (VAT). (24) However, growing evidence supports a similar process in PVAT. (17, 24, 42, 106) IL-1β, IL-6, MCP-1 and TNFα were shown to be higher in obese subjects undergoing bypass surgery in epicardial as opposed to subcutaneous fat. (42) . In related studies, in vitro differentiated human perivascular adipocytes demonstrated increased levels of IL-8, IL-6 and MCP-1 compared with subcutaneous adipose tissue. (17) The recognition that perivascular adipose inflammation potentially contributes to atherosclerosis has led to an 'outside-in' theory of vascular inflammation. The use of imaging modalities to quantitatively assess the amount of PVAT in specific perivascular fat depots has been fundamental to the epidemiological study of obesity and vascular disease. To date, most imaging of PVAT has focused on pericardial fat, which can be measured by ultrasound, multidetector computed tomography (MDCT) and MRI. (7, (109) (110) (111) . More recently, a reliable method for the assessment of periaortic fat volume has been developed. (112) The associations of epicardial and pericardial fat with metabolic risk factors, indices of myocardial structure and function and clinical vascular disease have been assessed in epidemiological studies. These studies have used multiple imaging modalities, and the terminology differs depending on the technique used. Echocardiographic studies generally use the term 'epicardial fat', whereas MDCT studies generally use the term 'pericardial fat'.(7,113) Epicardial thigh adipose tissue, it has the strongest correlation with insulin sensitivity in obese subjects and subjects with type 2 diabetes mellitus.
Second, vascular function, especially muscle perfusion, contributes to regulation of insulin-mediated glucose disposal. Increased amounts of adipose tissue, as observed in obese subjects and rats, are accompanied by impairment of muscle perfusion. Impairment of muscle perfusion has been estimated to account for 30% to 50% of insulin resistance. (117) Third, accumulation of PVAT around the arterioles that regulate muscle perfusion. Aside from intermuscular adipose tissue and PVAT around the femoral artery, we have found that PVAT exists within muscles (ie, intramuscular PVAT (mPVAT)). This location is especially relevant given the increasing evidence for regulation of muscle insulin sensitivity by microvascular perfusion in muscle. (117, 118) By regulating endothelium-dependent vasodilatation, insulin-mediated vasoreactivity, and muscle perfusion, mPVAT may control muscle glucose uptake and, thus, determine risk of future type 2 diabetes. (10) The mechanisms controlling the quantity of PVAT and adipokine secretion from PVAT remain to be determined. Because PVAT is related to insulin resistance, controls vascular function, and is located within insulin target tissues, it may well contribute to the pathogenesis of type 2 diabetes as well as cardiovascular disease. (10) In summary, PVAT is in close connection with the media of blood vessels, separated from it only by a very thin adventitial layer. The mass of perivascular fat increases in obesity and it is postulated that a paracrine secretion of various growth-stimulating and proinflammatory agents could contribute to the pathogenesis of cardiovascular diseases (6) . PVAT is increasingly recognized as a widespread, relevant tissue in vascular biology and important determinant of cardiometabolic complications of obesity.
Adipose tissue is an active endocrine and paracrine organ that may influence the development of atherosclerosis and vascular disease. In the setting of obesity, adipose tissue produces a variety of inflammatory cytokines (or adipokines) that are known to modulate key mechanisms of atherogenesis. In particular, adipose tissue located on the surface of the heart surrounding large coronary arteries (i.e. epicardial PVAT) has been implicated in the pathogenesis of coronary artery disease. The organism's perivascular adipocytes act as an integrated organ responsible for 
Conclusion
paracrine and vasocrine signalling, which in turn contributes to skeletal muscle insulin resistance.
The pathophysiology of PVAT in obesity and its influence on oxidative stress, inflammation, insulin resistance, endothelial dysfunction and vascular reactivity is well established. In addition, the contribution of specific epicardial perivascular adipose-derived adipokines (e.g. leptin, adiponectin) to the initiation and expansion of coronary disease is also evidenced. Future investigative with an emphasis on indentifying novel therapeutic targets and disease markers within PVAT are promising.
